Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Operating Leases (2020 - 2025)

Black Diamond Therapeutics' Operating Leases history spans 4 years, with the latest figure at $15.1 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 19.77% year-over-year to $15.1 million; the TTM value through Dec 2025 reached $15.1 million, down 19.77%, while the annual FY2025 figure was $15.1 million, 19.77% down from the prior year.
  • Operating Leases reached $15.1 million in Q4 2025 per BDTX's latest filing, down from $16.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $29.7 million in Q3 2021 to a low of $13.4 million in Q2 2021.
  • Average Operating Leases over 3 years is $18.5 million, with a median of $17.9 million recorded in 2025.
  • Peak YoY movement for Operating Leases: skyrocketed 3347.42% in 2021, then decreased 19.77% in 2025.
  • A 3-year view of Operating Leases shows it stood at $29.7 million in 2021, then plummeted by 36.71% to $18.8 million in 2024, then dropped by 19.77% to $15.1 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Operating Leases are $15.1 million (Q4 2025), $16.0 million (Q3 2025), and $17.0 million (Q2 2025).